Physician profile
Hung M Le
NPI 1811978182
$1,818.17
in general payments reported to CMS, 2019-2025
22 companies · $664 in 2025
The $664 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.72 · 2022: $183 · 2023: $229 · 2024: $693 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $436.20 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $204.68 | 2022-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $140.85 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $124.92 | 2024 | Vemlidy |
| Aimmune Therapeutics, INC. | $124.91 | 2025 | Zenpep |
| Incyte Corporation | $123.83 | 2025 | Opzelura |
| Lilly USA, LLC | $100.53 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Amgen INC. | $77.67 | 2024-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $57.74 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.65 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $47.50 | 2025 | |
| Merck Sharp & Dohme LLC | $42.87 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $42.74 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.50 | 2023-2024 | |
| Novo Nordisk INC | $39.33 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $38.52 | 2023-2025 | Nexletol |
| Pfizer INC. | $25.77 | 2025 | |
| Phathom Pharmaceuticals, INC. | $25.31 | 2024 | Voquezna |
| Theratechnologies INC. | $22.55 | 2024 | Trogarzo, Egrifta |
| Seqirus USA INC | $22.22 | 2025 | Fluad, Flucelvax |
| Abbvie INC. | $16.08 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.80 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.